More Teva moves to ease looming patent loss pain with Labrys buy

By Gareth Macdonald contact

- Last updated on GMT

More Teva moves to ease looming patent loss pain with Labrys buy

Related tags: Clinical trial, Teva

Teva Pharmaceutical Industries plans to buy Labrys Biologics for up to $825m to add a promising migraine treatment to its portfolio of pain drugs.

The deal – which will see Teva pay $200m upfront and up to $625m more on the achievement of certain milestones – is focused on the monoclonal antibody (mAb) LBR-101, which is currently in Phase II trials for chronic migraine​.

The drug was developed by Rinat Neurosciences. However, in 2006, it was bought​ by Pfizer along with a second mAb RN1219, since renamed PF-04360365, which is now in a Phase II trial​ for cerebral amyloid angiopathy after earlier studies in Alzheimer’s were unsuccessful​.

Teva said acquiring LBR-101 expands its pain portfolio which includes the blockbuster Copaxone – currently the subject of a complex patent battle​ – and a second migraine drug, Zecuity, gained in January​ though the takeover of NuPathe.

News of the planned Labrys deal comes just a day after Teva announced it will reorganise​ its executive team, appoint an overall chief of product quality and merge its generic business into a global unit under the leadership of Sigurdur Olafsson.

Related topics: Markets & Regulations

Related news

Follow us

Products

View more

Webinars